There is a global drive towards the repositioning of known drugs for cancer treatment due to high failure rate and cost of new drugs. Disulfiram (DS), an old anti-alcoholism drug, possesses excellent anticancer activity with low toxicity to normal cells. Unfortunately, the application of DS for cancer treatment is hindered by the extremely short half-life of DS in the bloodstream.

Prof. Wang's Experimental Cancer Therapeutic Research Group (ECTRG) at University of Wolverhampton (UoW) successfully used cutting-edge nano-drug-delivery technologies to extend the half-life of DS in the bloodstream, which manifests strong anticancer efficacy in animal models. This scientific breakthrough led to the establishment of a spin-out company Disulfican Ltd.

Disulfican has now developed a GMP quality human applicable nano-encapsulated DS as a novel anti-cancer therapy and are developing a pre-clinical data package prior to clinical trials. Our efforts have provided significant opportunity to develop an affordable effective anticancer drug within a shorter period of time which will be highly beneficial to cancer patients, NHS and the UK society.